Time to target haemoglobin concentration (11 g/dl) - Risk of hospitalization and mortality among incident dialysis patients

Nephrology Dialysis Transplantation

Volumn 22, Issue 8, 2007, Pages 2247-2255

  Ishani, Areef ^a,b   Guo, Haifeng ^a   Gilbertson, David T ^a   Liu, Jiannong ^a   Dunning, Stephan ^a   Collins, Allan J ^a,b,c   Foley, Robert N ^a,b,c  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Anaemia; Haemoglobin; Hospitalization; Mortality; Renal dialysis

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CHILD; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DIALYSIS; DIALYSIS CATHETER; FEMALE; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; INFANT; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; CHEMISTRY, CLINICAL; CHILD; CHILD, PRESCHOOL; FEMALE; HEMOGLOBINS; HOSPITALIZATION; HUMANS; INFANT; KIDNEY DISEASES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 34547851717     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm374     Document Type: Article

References (33)

1. U.S. Renal Data Syste. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004
2. National Kidney Foundation.NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 1997; 30 [Suppl 3]: S192-S240
3. St Peter WL, Obrador GT, Roberts TL et al. Trends in intravenous iron use among dialysis patients in the United States (1994-2002). Am J Kidney Dis 2005; 46: 650-660
4. Collins AJ, Ma JZ, Xia A et al. Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 1998; 32 [Suppl 4]: S133-S141
5. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis.Canadian Erythropoietin Study Group. Br Med J 1990; 300: 573-578
6. McMahon LP, Johns JA, McKenzie A et al. Hemodynamic changes and physical performance at comparative levels of hemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 1992; 7: 1199-1206
7. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590
8. Cannella G, La Canna G, Sandrini M et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991; 6: 31-37
9. Fellner SK, Lang RM, Neumann A et al. Cardiovascular consequences of correction of the anemia of renal failure with erythropoietin. Kidney Int 1993; 44: 1309-1315
10. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335
11. London GM, Zins B, Pannier B et al. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989; 36: 878-882
12. Pascual J, Teruel JL, Moya JL et al. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 1991; 35: 280-287
13. Silberberg J, Racine N, Barre P et al. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 1990; 6: 1-4
14. Churchill DN, Muirhead N, Goldstein M et al. Effect of recombinant human erythropoietin on hospitalization of hemodialysis patients. Clin Nephrol 1995; 43: 184-188
15. Collins AJ, Li S, Ebben J et al. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 2000; 36: 282-293
16. Ma JZ, Ebben J, Xia H et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619
17. Madore F, Lowrie EG, Brugnara C et al. Anemia in hemodialysis patients: Variables affecting this outcome predictor. J Am Soc Nephrol 1997; 8: 1921-1929
18. Ofsthun N, Labrecque J, Lacson E et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63: 1908-1914
19. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006; 17: 1181-1191
20. Robinson BM, Joffe MM, Berns JS et al. Anemia and mortality in hemodialysis patients: Accounting for morbidity and treatment variables updated over time. Kidney Int 2005; 68: 2323-2330
21. Xia H, Ebben J, Ma JZ et al. Hematocrit level and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999; 10: 1309-1316
22. D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281
23. Health Care Financing Administration, Department of Health and Human Services. Available at: www.medicare.gov/publications/pubs/pdf/ esrdcoverage.pdf page 12. Accessed 2 January 2007.
24. Singh AK, Szczech L, Tang KL et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. New Engl J Med 2006; 355: 2085-2098
25. Collins AJ, Brenner RM, Ofman JJ et al. Epoetin alfa use in patients with ESRD: An analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46: 481-488
26. Kausz AT, Solid C, Pereira BJ et al. Intractable anemia among hemodialysis patients: A sign of suboptimal management or a marker of disease? Am J Kidney Dis 2005; 45: 136-147
27. Fink J, Blahut S, Reddy M et al. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001; 37: 348-355
28. Collins AJ, Roberts TL, St Peter WL et al. United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis 2002; 39: 784-795
29. Fink JC, Hsu VD, Zhan M et al. Center effects in anemia management of dialysis patients. J Am Soc Nephrol 2007; 18: 646-653
30. Berns JS, Elzein H, Lynn RI et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 2003; 64: 1514-1521
31. Greenwood RN, Ronco C, Gastaldon F et al. Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance. Kidney Int 2003; 64; [Suppl 87]: S78-S86
32. Roberts TL, Foley RN, Weinhandl ED et al. Anaemia and mortality in hemodialysis patients: Interaction of propensity score for predicted anaemia and actual hemoglobin levels. Nephrol Dial Transplant 2006; 21: 1652-1662
33. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189